All In Biotech

Drug Trial Radar · NCT07802834

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Adjuvant ctDNA-Adapted Personalized Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Taiho Oncology, Inc.; National Comprehensive Cancer Network
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the novel, oral EGFR TKI, zipalertinib, in the adjuvant ctDNA-adapted treatment of stage IA2 to IIIC atypical EGFR-mutant NSCLC after completion of definitive therapy with a primary endpoint of molecular response in participants identified as having minimal residual disease (MRD).

Conditions

  • EGFR
  • Lung Cancer (NSCLC)
  • Non Small Cell Lung Cancer

Interventions

  • ZipalertinibDrug

    Zipalertinib will be administered to participants allocated to the Treatment MRD+ Arm of this study on the basis of MRD positivity at study entry or on repeat assessment. Zipalertinib will begin on Cycle 1 Day 1 and will be self-administered at 100 mg oral (PO) twice daily (BID) every day in each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Molecular response rate at 12 weeksTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.